Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...
SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 /CenExel is pleased to announce its partnership with Metsera, Inc.
Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...
BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating ...
Cantor Fitzgerald initiated coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage issued an overweight rating on the stock.
Guggenheim initiated coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $ ...
On Tuesday, Cantor Fitzgerald began coverage of Metsera Inc (NASDAQ:MTSR) with an Overweight rating, highlighting the biotech company's potential in the obesity drug market. The firm's analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results